Clinical Pathways Helped Health System Lower Costs, Boost Trial Enrollment Across Multiple Sites
June 25th 2020The savings occurred even while more patients in the health system were enrolling in clinical trials, according to an abstract presented during the American Society of Clinical Oncology 2020 Virtual meeting.
Read More
CMS Issues Rules to Promote Value-Based Contracting, Pay for High-Cost Therapies in Medicaid
June 18th 2020Administrator Seema Verma said the proposal would create opportunities "for drug manufacturers to have skin in the game through payment arrangements that challenge them to put their money where their mouth is."
Read More
How Does Cardiotoxicity Present Itself in Patients With Cancer?
June 12th 2020Three abstracts presented at this year’s annual meeting of the American Society of Clinical Oncology focused on cardiotoxic effects of cancer treatment and how cardiac disease remains a barrier to effective cancer therapy among patients with cancer and survivors.
Read More
Care Not in Line With Guidelines for HER2-Negative MBC Has Worse Outcomes in Elderly Women
May 23rd 2020More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.
Read More
Collaboration Leads to Clinical Pathways Success for One Illinois Practice
May 22nd 2020Cancer Care Specialists of Illinois was able to reduce its median total drug spend by a notable 13.5%—$250,000 per medical oncologist—versus other practices enrolled in the Oncology Care Model, between the first quarters of 2017 and 2019, through the use of evidence-based clinical pathways.
Read More
Clinical Pathways: Reducing Costs and Improving Quality Across a Network
February 19th 2020As the cost of oncology drugs only continues to rise, incorporating clinical pathways into cancer care helps streamline the integration of evidence-based best practices while improving quality and reducing costs for patients and payers.
Read More
Lessons From the Front: Designing and Implementing Clinical Pathways by and for Clinicians
As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.
Read More
US Care Pathways: Continued Focus on Oncology and Outstanding Challenges
The authors examined the latest trends in development, implementation, and evaluation of care pathways and the impact of the movement toward value-based care.
Read More
NCCN Releases Clinical Practice Guidelines for Pediatric ALL
May 30th 2019The National Comprehensive Cancer Network (NCCN) Thursday released its first set of clinical practice guidelines for pediatric cancer, saying the new acute lymphoblastic leukemia (ALL) guidelines are the first of several planned to address various pediatric cancers.
Read More
Roadmap to Success in the Oncology Care Model: Tapping Into Human Potential via Sustained Engagement
December 27th 2018The authors, led by Kashyap Patel, MD, offer the first in a series of articles on how Carolina Blood and Cancer Care Associates leveraged the strength of its team to take part in the Oncology Care Model.
Read More
Analysis Shows Benefit of Abemaciclib in Women With Worse Prognosis
December 19th 2018A recent study of abemaciclib, a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer, found that it helped all women with hormone receptor–positive, human epidermal growth factor receptor 2–negative disease, and that it was particularly beneficial in women with a worse prognosis.
Read More
BCI Index Helps Clinicians Individualize Patient Treatment
December 14th 2018During the San Antonio Breast Cancer Symposium held in San Antonio, Texas from December 4-8, 2018, Biotheranostics presented new data evaluating the impact of the Breast Cancer Index (BCI) in patients with early stage hormone receptor positive (HR+) breast cancer who are classified as an immediate risk for distant recurrence by previous genomic testing.
Read More